OVERVIEW
Breast Cancer: Neoadjuvant/Adjuvant
Breast Cancer: Adjuvant (Residual Disease Post-Neoadjuvant Treatment)
Breast Cancer: Metastatic and Recurrent – Endocrine Therapy
Breast Cancer: Metastatic and Recurrent – Chemotherapy
Pancreatic Cancer: Neoadjuvant (Resectable/Borderline Resectable)
Pancreatic Cancer: Adjuvant (Resectable)
Pancreatic Cancer: Locally Advanced/Metastatic
Melanoma: Adjuvant (Resectable) – Stg IIIB/IIIC
Melanoma: Adjuvant (Resectable) – Stg IIIB/IIIC (BRAF Mutated)
Melanoma: Metastatic/Unresectable (BRAF Mutated/Symptomatic)
Melanoma: Metastatic/Unresectable (BRAF Wild Type/Mutated/Unknown)
Colon Cancer: Adjuvant
Colon Cancer: Metastatic KRAS/NRAS: Unknown/Mutant
Colon Cancer: Metastatic KRAS/NRAS: Wild Type
OVERVIEW

Cancer Therapy Pathways Program
With the rapid approval of new therapies, along with the rising cost of cancer care, pathways serve a critical role in the delivery of high-quality and high-value cancer treatments while reducing an unwarranted variation in care. UnitedHealthcare’s Cancer Therapy Pathways Program aims to improve quality and value in cancer care by identifying anti-cancer regimens supported by evidence-based guidelines to help reduce total cost of care and improve outcomes. The program’s regimens are selected on the basis of clinical benefit (efficacy) and side-effect profile (toxicity). Among regimens with comparable efficacy and toxicity, additional consideration is given to the frequency of hospitalizations during therapy, duration of therapy, drug costs and total cost of care.

Care Decisions Are Between the Physician and the Patient
The Cancer Therapy Pathways Program is not a substitute for the experience and judgment of a physician or other health care professional. Any clinician participating in the program must use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Care decisions are between the physician and patient.
Breast Cancer: Neoadjuvant/Adjuvant

HER2 NEGATIVE:
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel weekly (ddAC → weekly T)
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel every 2 weeks (ddAC → q2w T)
- Docetaxel + Cyclophosphamide (TC)

HER2 POSITIVE:
- Doxorubicin + Cyclophosphamide → Paclitaxel weekly + Trastuzumab* (AC→TH)
- Docetaxel + Carboplatin + Trastuzumab* (TCH)
- Paclitaxel + Trastuzumab*

Breast Cancer: Adjuvant (Residual Disease Post-Neoadjuvant Treatment)

HER2 NEGATIVE:
- Capecitabine

HER2 POSITIVE:
- Ado-trastuzumab emtansine (T-DM1)

Breast Cancer: Metastatic and Recurrent – Endocrine Therapy

HER2 NEGATIVE:
1st Line of Therapy
- Anastrozole
- Letrozole
- Exemestane
- Tamoxifen
- Fulvestrant
- Anastrozole + Palbociclib
- Letrozole + Palbociclib
- Exemestane + Palbociclib
- Anastrozole + Abemaciclib
- Letrozole + Abemaciclib
- Exemestane + Abemaciclib

HER2 NEGATIVE:
2nd + Subsequent Lines of Therapy
- Anastrozole
- Letrozole
- Exemestane
- Tamoxifen
- Fulvestrant
- Anastrozole + Palbociclib
- Letrozole + Palbociclib
- Exemestane + Palbociclib
- Anastrozole + Abemaciclib
- Letrozole + Abemaciclib
- Exemestane + Abemaciclib
• Fulvestrant + Palbociclib
• Fulvestrant + Abemaciclib

**HER2 POSITIVE:**
• Anastrozole + Trastuzumab*
• Letrozole + Trastuzumab*
• Exemestane + Trastuzumab*
• Anastrozole + Lapatinib
• Letrozole + Lapatinib
• Exemestane + Lapatinib

**Breast Cancer: Metastatic and Recurrent – Chemotherapy**

**HER2 NEGATIVE:**

1st + Subsequent Lines of Therapy
• Doxorubicin
• Paclitaxel
• Docetaxel
• Capecitabine
• Gemcitabine
• Vinorelbine
• Atezolizumab + Nab-paclitaxel (in PD-L1+ mTNBC only)

**HER2 POSITIVE:**

1st + Subsequent Lines of Therapy
• Docetaxel + Trastuzumab* + Pertuzumab
• Paclitaxel + Trastuzumab* + Pertuzumab
• Ado-Trastuzumab Emtansine (T-DM1)
• Paclitaxel + Trastuzumab*
• Vinorelbine + Trastuzumab*
• Gemcitabine + Trastuzumab*
• Capecitabine + Trastuzumab*

* Kanjinti™ is the preferred product under UnitedHealthcare commercial and UnitedHealthcare community plans (in most markets) and all products preferred under UnitedHealthcare Medicare plans.
References:


Pancreatic Cancer: Neoadjuvant (Resectable/Borderline Resectable)
- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/mFOLFIRINOX)
- Gemcitabine + Albumin-bound Paclitaxel (G-nP)

Pancreatic Cancer: Adjuvant (Resectable)
- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (mFOLFIRINOX)
- Gemcitabine + Capecitabine
- Gemcitabine

Pancreatic Cancer: Locally Advanced/Metastatic

1st Line of Therapy
- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/mFOLFIRINOX)
- Gemcitabine + Albumin-bound Paclitaxel (G-nP)
- Gemcitabine

2nd + Subsequent Lines of Therapy
- Gemcitabine + Albumin-bound Paclitaxel (G-nP)
- Gemcitabine
- Fluorouracil/Leucovorin + Oxaliplatin (OFF)
- Fluorouracil/Leucovorin + Oxaliplatin (FOLFOX)
- Fluorouracil/Leucovorin + Irinotecan (FOLFIRI)
References:


Melanoma: Adjuvant (Resectable) – Stg IIIB/IIIC

- Pembrolizumab
- Nivolumab

Melanoma: Adjuvant (Resectable) – Stg IIIB/IIIC (BRAF Mutated)

- Dabrafenib + Trametinib

Melanoma: Metastatic/Unresectable (BRAF Mutated/Symptomatic)

- Vemurafenib + Cobimetinib

Melanoma: Metastatic/Unresectable (BRAF Wild Type/Mutated/Unknown)

1st + Subsequent Lines of Therapy

- Pembrolizumab
- Nivolumab
- Nivolumab + Ipilimumab
References:


Colon Cancer: Adjuvant

- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX)
- Fluorouracil (5-FU)/Leucovorin

Colon Cancer: Metastatic KRAS/NRAS: Unknown/Mutant

1st and 2nd Lines of Therapy

- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) +/- Bevacizumab*
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) +/- Bevacizumab*
- Capecitabine

Colon Cancer: Metastatic KRAS/NRAS: Wild Type

1st and 2nd Lines of Therapy

- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) + Cetuximab
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) + Cetuximab
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) + Panitumumab
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) + Panitumumab
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) +/- Bevacizumab*
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) +/- Bevacizumab*
- Capecitabine

* Mvasi™ is the preferred product under UnitedHealthcare commercial and UnitedHealthcare Community Plans (in most markets) and all products preferred under UnitedHealthcare Medicare plans.
References:


prespecified subgroup analyses from the VELOUR trial. Retrieved from

second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre,


oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in
metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology

metastatic colorectal cancer. Retrieved from Initial therapy with FOLFOXIRI and bevacizumab for metastatic
colorectal cancer.

plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival
and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Retrieved from

treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical

leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Retrieved from

capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-

regimens in second-line therapy of metastatic colorectal cancer. Retrieved from

metastatic colorectal carcinoma. Retrieved from


57. Venook, A. P., Niedzwiecki, D., Lenz, H.J., et al. (2017, June 20). Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on Overall Survival in Patients with KRAS Wild-Type Advanced or Metastatic


© 2020 United HealthCare Services, Inc.